ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

9 links4 made here, not in the record7 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05349383Evaluation of Reporting ofAntibody-Drug ConjugateAssociated Sepsis-relatedToxicitiesCentral South UniversitycompletedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSSepsisThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionOpportunistic InfectionsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.AgranulocytosisThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSAntibody-drug conjugates (A…Entry “Antibody-Drug Conjugate”, read…›Nov 18 · Rule based · ExposureExposureTrastuzumab deruxtecanMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ExposureExposureSacituzumab govitecanMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ExposureExposureEnfortumab vedotinMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · ExposureExposureAdo-Trastuzumab EmtansineMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · ExposureExposureTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Trastuzumab deruxtecan

Made here1 judgment on this link
NCT05349383gives it, found by reading the recordTrastuzumab deruxtecanDefined by Claude Opus 5.5Nov 3, 2026, 6:51 AM UTC
Role in the study, from the registry to what was judged
RegistryNot in the recordno intervention entry names it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2TrastuzumabClaude Opus 5.5Not givenCurrent
Nov 3Trastuzumab deruxtecanmade hereClaude Opus 5.5ExposureCurrent
Nov 3Sacituzumab govitecanmade hereClaude Opus 5.5ExposureCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 10Enfortumab vedotinmade hereClaude Opus 5.5ExposureCurrent
Nov 10Ado-Trastuzumab Emtansinemade hereClaude Opus 5.5ExposureCurrent
Nov 18Antibody-drug conjugates (ADCs)Rule based · role ruleExposureCurrent
As of nowSepsisRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.